Research progress of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of inflammatory and immune-mediated diseases
10.11665/j.issn.1000-5048.2023121103
- VernacularTitle:布鲁顿酪氨酸激酶(BTK)抑制剂在治疗炎症免疫性疾病中的研究进展
- Author:
Weijie REN
1
;
Lifang CEN
;
Yi ZOU
Author Information
1. 中国药科大学药学院
- Publication Type:Journal Article
- Keywords:
BTK / inflammatory immunity / autoimmune diseases / allergy / clinical research
- From:
Journal of China Pharmaceutical University
2024;55(1):63-72
- CountryChina
- Language:Chinese
-
Abstract:
Abstract: Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in the activation of B cells and granulocytes, operating downstream of B cell and Fcγ receptors, and is considered an attractive target for treating autoimmune diseases. Preclinical investigations have demonstrated that inhibition of BTK activity holds promise as a potential therapeutic strategy for inflammatory immune responses such as autoimmune diseases and allergies. This review provides an overview of the mechanisms by which BTK contributes to immune-related diseases and summarizes current research on the development of BTK inhibitors for treating these conditions, aiming to offer novel insights into non-oncology applications for BTK inhibitors.
